[go: up one dir, main page]

TN2009000197A1 - Sustained - release composition and method for producing the same - Google Patents

Sustained - release composition and method for producing the same

Info

Publication number
TN2009000197A1
TN2009000197A1 TNP2009000197A TN2009000197A TN2009000197A1 TN 2009000197 A1 TN2009000197 A1 TN 2009000197A1 TN P2009000197 A TNP2009000197 A TN P2009000197A TN 2009000197 A TN2009000197 A TN 2009000197A TN 2009000197 A1 TN2009000197 A1 TN 2009000197A1
Authority
TN
Tunisia
Prior art keywords
sustained
physiologically active
producing
same
release
Prior art date
Application number
TNP2009000197A
Other languages
English (en)
Inventor
Tomomichi Futo
Kazuhiro Saito
Tetsuo Hoshino
Masuhisa Hori
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39015849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000197(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2009000197A1 publication Critical patent/TN2009000197A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
TNP2009000197A 2006-12-18 2009-05-20 Sustained - release composition and method for producing the same TN2009000197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87536406P 2006-12-18 2006-12-18
US91740107P 2007-05-11 2007-05-11
PCT/JP2007/074617 WO2008075762A1 (fr) 2006-12-18 2007-12-17 Composition à libération prolongée et procédé de production correspondant

Publications (1)

Publication Number Publication Date
TN2009000197A1 true TN2009000197A1 (en) 2010-10-18

Family

ID=39015849

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000197A TN2009000197A1 (en) 2006-12-18 2009-05-20 Sustained - release composition and method for producing the same

Country Status (27)

Country Link
US (3) US8921326B2 (fr)
EP (1) EP2094246B1 (fr)
JP (2) JP4564098B2 (fr)
KR (1) KR101522035B1 (fr)
CN (1) CN101563068B (fr)
AR (1) AR064381A1 (fr)
AU (1) AU2007335406B2 (fr)
BR (1) BRPI0720582B1 (fr)
CA (1) CA2671670C (fr)
CL (1) CL2007003658A1 (fr)
CO (1) CO6180498A2 (fr)
CR (1) CR10867A (fr)
DO (1) DOP2009000144A (fr)
EA (1) EA016176B1 (fr)
EC (1) ECSP099439A (fr)
ES (1) ES2791698T3 (fr)
GE (1) GEP20125597B (fr)
IL (1) IL198845A (fr)
MA (1) MA31006B1 (fr)
MX (1) MX2009006653A (fr)
MY (1) MY148370A (fr)
NO (1) NO347209B1 (fr)
NZ (1) NZ577281A (fr)
PE (1) PE20081842A1 (fr)
TN (1) TN2009000197A1 (fr)
TW (1) TWI481424B (fr)
WO (1) WO2008075762A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
SG181436A1 (en) * 2009-12-22 2012-07-30 Takeda Pharmaceutical Sustained-release formulation
EP2585091B1 (fr) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Formule à libération prolongée comprenant un dérivé de metastin
WO2013161778A1 (fr) * 2012-04-24 2013-10-31 国立大学法人大阪大学 Procédé de production d'une dispersion aqueuse de nanoparticules de médicament et son utilisation
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
WO2015158823A1 (fr) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Composition pharmaceutique vétérinaire et utilisation de ladite composition pharmaceutique vétérinaire
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
WO2019066649A1 (fr) * 2017-09-26 2019-04-04 Nanomi B.V. Procédé de préparation de microparticules par une technique de double émulsion
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
CN112955181B (zh) 2019-03-26 2024-08-13 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
BR112022000413A2 (pt) * 2019-07-12 2022-03-03 G2Gbio Inc Formulação de longa duração contendo rivastigmina e método para preparar a mesma
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1236641A (fr) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymere d'acide lactique et d'acide glycolique et methode de production
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
CA2040141C (fr) 1990-04-13 2002-05-14 Minoru Yamada Polymeres biodegradables a haute densite moleculaire production et utilisation desdits polymeres
JP3116311B2 (ja) 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
FR2693905B1 (fr) 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DE4342092B4 (de) 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
ATE178789T1 (de) 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
JPH07273447A (ja) 1994-03-29 1995-10-20 Sumitomo Kinzoku Ceramics:Kk セラミック回路基板及びその製造方法
US5763513A (en) 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
FR2736508B1 (fr) 1995-07-13 1997-09-19 Francais Prod Ind Cfpi Nouvelle forme solide de stockage et de commercialisation pour compositions phytosanitaires et moyens pour sa preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192782C (fr) 1995-12-15 2008-10-14 Nobuyuki Takechi Production de microsphere
CA2192773C (fr) 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
US6740634B1 (en) * 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
KR20010086245A (ko) 1998-03-04 2001-09-10 다케다 야쿠힌 고교 가부시키가이샤 Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도
US6114495A (en) 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
PT1158014E (pt) 1998-12-15 2005-04-29 Takeda Pharmaceutical Processo para a producao de poliesteres biodegradaveis
RU2002103718A (ru) 1999-07-15 2003-10-10 Такеда Кемикал Индастриз, Лтд. (JP) Композиции пролонгированного действия, способы их получения и применение
AU6510400A (en) 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
DE60118575T3 (de) 2000-08-07 2011-05-19 Takeda Pharmaceutical Co. Ltd. Milchsäurepolymer und verfahren zu dessen herstellung
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002043766A1 (fr) 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
AU2002221139A1 (en) 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
CA2471521C (fr) 2001-12-26 2010-11-02 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
CA2490351C (fr) 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Procede de production d'une composition a liberation prolongee
US6803708B2 (en) * 2002-08-22 2004-10-12 Cdream Display Corporation Barrier metal layer for a carbon nanotube flat panel display
EP2462923A3 (fr) 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Prévention de la réduction du poids moléculaire du polymère, de la formation d'impuretés et de la gélification de compositions polymères
BRPI0412211A (pt) 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
US20050152911A1 (en) * 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
TW200613012A (en) 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
NZ554426A (en) 2004-10-01 2010-05-28 Ramscor Inc Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
JP5244394B2 (ja) 2004-11-10 2013-07-24 トルマー セラピューティクス， インコーポレイテッド． 安定化されたポリマー送達系
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same

Also Published As

Publication number Publication date
EA016176B1 (ru) 2012-02-28
MY148370A (en) 2013-04-15
TW200833376A (en) 2008-08-16
US9713595B2 (en) 2017-07-25
JP5258844B2 (ja) 2013-08-07
DOP2009000144A (es) 2009-07-30
PE20081842A1 (es) 2009-01-19
CO6180498A2 (es) 2010-07-19
AU2007335406B2 (en) 2012-09-13
KR101522035B1 (ko) 2015-05-20
IL198845A0 (en) 2010-02-17
ECSP099439A (es) 2009-07-31
US20110135741A1 (en) 2011-06-09
CN101563068A (zh) 2009-10-21
IL198845A (en) 2015-07-30
CA2671670C (fr) 2015-02-10
JP2010513225A (ja) 2010-04-30
US20150080322A1 (en) 2015-03-19
ES2791698T3 (es) 2020-11-05
US20170165204A1 (en) 2017-06-15
NO347209B1 (no) 2023-07-03
MX2009006653A (es) 2009-07-02
BRPI0720582A2 (pt) 2014-02-04
CL2007003658A1 (es) 2008-05-09
CR10867A (es) 2009-07-30
TWI481424B (zh) 2015-04-21
NZ577281A (en) 2011-12-22
JP4564098B2 (ja) 2010-10-20
US9617303B2 (en) 2017-04-11
EA200970600A1 (ru) 2009-12-30
BRPI0720582B1 (pt) 2021-08-24
KR20090094272A (ko) 2009-09-04
GEP20125597B (en) 2012-08-10
NO20092662L (no) 2009-09-07
AR064381A1 (es) 2009-04-01
WO2008075762A1 (fr) 2008-06-26
JP2010222371A (ja) 2010-10-07
CN101563068B (zh) 2013-03-20
EP2094246A1 (fr) 2009-09-02
AU2007335406A1 (en) 2008-06-26
EP2094246B1 (fr) 2020-04-01
US8921326B2 (en) 2014-12-30
CA2671670A1 (fr) 2008-06-26
MA31006B1 (fr) 2009-12-01

Similar Documents

Publication Publication Date Title
TN2009000197A1 (en) Sustained - release composition and method for producing the same
US20190358332A1 (en) Oral product with alginate composition of releasable substance
MXPA05012791A (es) Formulacion sostenida que contiene dimeticona.
EP1786400A4 (fr) Compositions pharmaceutiques permettant la liberation progressive de composes bioactifs
TW200608975A (en) Pharmaceutical compositions
WO2008157614A3 (fr) Administration soutenue de médicament à partir de microparticules polymères biodégradables
RU2004111596A (ru) Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
CA2468703A1 (fr) Compositions polymeres a liberation controlee de composes stimulant la formation osseuse
ATE322513T1 (de) Milchsäurepolymer und verfahren zu dessen herstellung
MY139606A (en) Sustained-release composition and process for producing the same
FR2954165A1 (fr) Compositions injectables a usage intra-articulaire associant un agent de viscosupplementation et un milieu de croissance des fibroblastes
TN2009000476A1 (en) Slow release pharmaceutical composition made of microparticles
MY151468A (en) Controlled release solid preparation
WO2004078111A3 (fr) Compositions de minocycline a liberation prolongee et leurs procedes de preparation
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
UA97125C2 (ru) Композиция продолжительного высвобождения и способ ее получения
BRPI0606373A2 (pt) composição de xarope compreendendo dexibuprofeno como ingrediente ativo e método para a preparação da mesma
RU2007143556A (ru) Композиции с пролонгированным высвобождением
RU2011108370A (ru) Жевательная композиция, включающая альгинат, бикарбонат и карбонат
EP1634585A4 (fr) Microparticule a liberation prolongee contenant un medicament, procede de production correspondant et preparation contenant ladite microparticule
Tarawneh et al. Development and characterization of k-carrageenan platforms as periodontal intra-pocket films
NZ596275A (en) Burst drug release compositions
WO2007015270A3 (fr) Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine
WO2002017877A3 (fr) Compositions pour granules pharmaceutiques a liberation controlee destinees a limiter les effets secondaires de medicaments
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением